cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Corbus Pharmaceuticals Holdings Inc
66 own
77 watching
Current Price
$6.5
$-0.19
(-2.84%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
39.29M
52-Week High
52-Week High
13.17000
52-Week Low
52-Week Low
2.11000
Average Volume
Average Volume
0.02M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization39.29M
icon52-Week High13.17000
icon52-Week Low2.11000
iconAverage Volume0.02M
iconDividend Yield--
iconP/E Ratio--
What does the Corbus Pharmaceuticals Holdings Inc do?
Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases. Its lead product candidate includes JBT-101, a novel oral endocannabinoid-mimetic drug, which is in Phase 2 clinical trials for the treatment of systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis, and systemic lupus erythematosus diseases. The company is based in Norwood, Massachusetts.
Read More
How much money does Corbus Pharmaceuticals Holdings Inc make?
News & Events about Corbus Pharmaceuticals Holdings Inc.
PR Newswire
7 months ago
Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on CRB-601 av8 Blocking Antibody at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy Meeting Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on CRB-601 av8 Blocking Antibody at the New York Academy of Sciences...
PR Newswire
8 months ago
Thinking about buying stock in Corbus Pharmaceuticals, Marathon Digital, Riot Platforms, CleanSpark, or BigBear.ai? Thinking about buying stock in Corbus Pharmaceuticals, Marathon Digital, Riot Platforms, CleanSpark, or BigBear.ai? PR Newswire NEW YORK, March 17, 2023 NEW YORK, March 17, 2023...
PR Newswire
1 year ago
Thinking about buying stock in Nio, Kalera, Salesforce, Corbus Pharmaceuticals, or Full Truck Alliance? Thinking about buying stock in Nio, Kalera, Salesforce, Corbus Pharmaceuticals, or Full Truck Alliance? PR Newswire NEW YORK, Nov. 30, 2022 NEW YORK, Nov. 30, 2022 /PRNewswire...
PR Newswire
1 year ago
Corbus Pharmaceuticals to Present Pre-Clinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting Corbus Pharmaceuticals to Present Pre-Clinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting PR Newswire NORWOOD, Mass...
PR Newswire
1 year ago
Thinking about buying stock in Aditxt, RedHill Biopharma, Corbus Pharmaceuticals, Li Auto, or Kiora Pharmaceuticals? Thinking about buying stock in Aditxt, RedHill Biopharma, Corbus Pharmaceuticals, Li Auto, or Kiora Pharmaceuticals? PR Newswire NEW YORK, Sept. 26, 2022 NEW YORK, Sept. 26, 2022...
Frequently Asked Questions
Frequently Asked Questions
What is Corbus Pharmaceuticals Holdings Inc share price today?
plus_minus_icon
Can Indians buy Corbus Pharmaceuticals Holdings Inc shares?
plus_minus_icon
How can I buy Corbus Pharmaceuticals Holdings Inc shares from India?
plus_minus_icon
Can Fractional shares of Corbus Pharmaceuticals Holdings Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Corbus Pharmaceuticals Holdings Inc stocks?
plus_minus_icon
What is today’s traded volume of Corbus Pharmaceuticals Holdings Inc?
plus_minus_icon
What is today’s market capitalisation of Corbus Pharmaceuticals Holdings Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Corbus Pharmaceuticals Holdings Inc?
plus_minus_icon
What percentage is Corbus Pharmaceuticals Holdings Inc down from its 52-Week High?
plus_minus_icon
What percentage is Corbus Pharmaceuticals Holdings Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$6.5
$-0.19
(-2.84%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc.
$7.25
$-0.60 (-7.64 %)
Chimerix Inc
Chimerix Inc
$1.01
$0.04 (4.12 %)
Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc.
$0.21
$0.00 (1.96 %)
Abeona Therapeutics Inc.
Abeona Therapeutics Inc.
$4.66
$-0.14 (-2.92 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc.
$7.25
$-0.60 (-7.64 %)
Chimerix Inc
Chimerix Inc
$1.01
$0.04 (4.12 %)
Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc.
$0.21
$0.00 (1.96 %)
Abeona Therapeutics Inc.
Abeona Therapeutics Inc.
$4.66
$-0.14 (-2.92 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00